Last $70.14 USD
Change Today -0.96 / -1.35%
Volume 1.8M
DGX On Other Exchanges
New York
As of 4:15 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

quest diagnostics inc (DGX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/3/15 - $72.86
52 Week Low
03/10/14 - $51.86
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for QUEST DIAGNOSTICS INC (DGX)

quest diagnostics inc (DGX) Related Businessweek News

View More BusinessWeek News

quest diagnostics inc (DGX) Details

Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry. It also develops, manufactures, and markets diagnostic products, including Simplexa molecular chemistries for testing infectious disease and hospital-acquired infections; HerpeSelect HSV serology; and DxSelect IFA and ELISA products for testing infectious diseases. In addition, the company offers molecular diagnostic products in various segments, such as HIV-1 drug resistance testing under the ViroSeq brand name; and reproductive genetics and transplantation under the Atria and AlleleSeqr brand names. Further, it provides Care360 EHR, a solution that allows doctors to electronically create, manage, and distribute patient encounter notes, as well as for patient communication through a patient portal; and ChartMaxx, an enterprise content management system for hospitals. The company primarily offers its diagnostic information services under the Quest Diagnostics, AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Solstas, and Summit Health brands to patients, physicians, hospitals, accountable care organizations, integrated delivery networks, health plans, employers, and other customers through a network of laboratories, patient service centers, and phlebotomists in physician offices. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey.

45,000 Employees
Last Reported Date: 02/24/15
Founded in 1967

quest diagnostics inc (DGX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $1.1M
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $472.1K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $573.9K
Senior Vice President of Clinical Franchises
Total Annual Compensation: $520.0K
Vice President of Joint Ventures and Strategi...
Total Annual Compensation: $565.0K
Compensation as of Fiscal Year 2013.

quest diagnostics inc (DGX) Key Developments

Genomic Vision Renews its Strategic Collaboration with Quest Diagnostics for Three More Years

Genomic Vision announced that it has signed an amendment to its contract with Quest Diagnostics to extend their strategic collaboration based on Genomic Vision's technology. The amendment extends the collaboration for three more years, until November 2018. Under the terms of the amendment, Quest Diagnostics retains exclusive rights to develop, validate and market tests based on molecular combing in the fields of breast and ovarian cancer, such as BRCA gene mutation testing, hereditary colon cancer (Lynch syndrome), spinal muscular atrophy (SMA) and facioscapulohumeral muscular distrophy (FSHD) in the United States, India and Mexico. Genomic Vision will continue to retain exclusive rights to market its tests in Europe, the Middle East and Africa, per the original agreement with Quest. Quest Diagnostics, an equity owner in Genomic Vision, has granted Genomic Vision rights to seek to develop new diagnostic tests in partnership with other providers of diagnostic services or medical centers in the United States and to market them all over the world. Genomic Vision will be able to accelerate the number of diagnostic tests offered utilizing its technology by working with leaders in many fields worldwide. Quest will receive credits against milestone payments earned by Genomic Vision in consideration for the rights granted. The royalty rate paid to Genomic Vision by Quest Diagnostics for the provision of testing services based on laboratory-developed molecular combing tests will increase significantly.

Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation

Quest Diagnostics announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation. Under the agreement, Quest Diagnostics and Myriad Genetics and its co-parties in the litigation, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche Inc. dismiss their lawsuits, claims, counterclaims and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation. Myriad has also provided Quest Diagnostics and its physician, hospital and other customers and business partners a covenant not to sue with respect to the patents at issue. Quest Diagnostics has the right to continue to offer its BRCAvantage and other BRCA-related testing services in their present form and to develop and provide additional genomic testing services in the future based on the portfolio of patents asserted by Myriad in this case.

Quest Diagnostics Inc. Provides Investments Plans

Quest Diagnostics Inc. estimates up to $300 million in investments over the next 3 years.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DGX:US $70.14 USD -0.96

DGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cepheid $56.84 USD -1.60
Hologic Inc $32.38 USD +0.17
Myriad Genetics Inc $34.07 USD -0.89
QIAGEN NV €22.50 EUR +0.32
View Industry Companies

Industry Analysis


Industry Average

Valuation DGX Industry Range
Price/Earnings 18.8x
Price/Sales 1.4x
Price/Book 2.4x
Price/Cash Flow 15.8x
TEV/Sales 0.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUEST DIAGNOSTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at